Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
GABA shows no beta-cell regeneration in type 1 diabetes
Última actualización 9 de septiembre de 2026
Key finding
No effect on fasting C-peptide levels were identified during the course of study.
This study investigated the effects of GABA on beta-cell regeneration in adults with long-standing type 1 diabetes, finding no significant improvements in key outcomes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of GABA on beta-cell regeneration in adults with long-standing type 1 diabetes, finding no significant improvements in key outcomes.
Clinical relevance
Understanding the effectiveness of potential therapies like GABA is crucial for developing new treatments for type 1 diabetes. The lack of positive results highlights the challenges in finding effective interventions for long-standing diabetes and informs future research directions.
Keep in mind
The study had a small sample size, limiting generalizability. No significant effects were observed, indicating unclear effectiveness. Participants experienced treatment-related adverse effects.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Henrik H, Per L, Georgios T, Bryndis B, Daniel E, Per-Ola C. Gamma-amino butyric acid (GABA) as a potential beta-cell regenerative therapy in adults with long-standing type 1 diabetes. Scientific Reports. 2025;15:11530. doi:10.1038/s41598-025-95751-y
Efectos Principales
No effect on fasting C-peptide levels was identified.
No effect on stimulated C-peptide levels was identified.
No improvement in HbA1c levels was observed.
Hypoglycemic hormonal counter-regulation was unaltered.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to GABA 200 mg and C-peptide, Counter-regulatory hormone response to hypoglycemia, Elevated liver transaminase, and 2 more.
This study contributes evidence to
Primary intervention
GABA 200 mg
Primary outcomes
- C-peptide
- Counter-regulatory hormone response to hypoglycemia
- Elevated liver transaminase
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
2
Related topics
5
Evidence pairs
632
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
C-Peptide
matched_outcome
Evidencia relacionada
Tema de evidencia
HbA1c Reduction
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Counter-regulatory hormone response to hypoglycemia
GABA 200 mg → Counter-regulatory hormone response to hypoglycemia
GABA 200 mg → Counter-regulatory hormone response to hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerElevated liver transaminase
GABA 200 mg → Elevated liver transaminase
GABA 200 mg → Elevated liver transaminase
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerFasting C-peptide levels
GABA 200 mg → Fasting C-peptide levels
GABA 200 mg → Fasting C-peptide levels
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- GABA treatment did not improve fasting or stimulated C-peptide levels.
- HbA1c levels remained unchanged across treatment arms.
- Two participants discontinued due to elevated liver transaminase levels.
A quién se aplica
- Adults with long-standing type 1 diabetes.
- Participants experiencing challenges in glycemic control.
Tener en Cuenta
- Results may not be applicable to younger populations or those with recent-onset diabetes.
- The study did not assess long-term effects beyond the treatment period.
- Further research is needed to explore alternative therapies for beta-cell regeneration.
Entre Líneas
- The study had a small sample size, limiting generalizability.
- No significant effects were observed, indicating unclear effectiveness.
- Participants experienced treatment-related adverse effects.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GABA 200 mg and C-peptide Levels, GABA 200 mg and Counter-regulatory hormone response to hypoglycemia.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GABA 200 mg → C-peptide Levels
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
C-peptide Levels Evidence Hub
All studies measuring C-peptide Levels
1 studies
outcome_hubMeasures C-peptide Levels as a key outcome.
Counter-regulatory hormone response to hypoglycemia Evidence Hub
All studies measuring Counter-regulatory hormone response to hypoglycemia
1 studies
outcome_hubMeasures Counter-regulatory hormone response to hypoglycemia as a key outcome.
GABA 200 mg Evidence Hub
All studies on GABA 200 mg
1 studies
intervention_hubContributes to GABA 200 mg evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on GABA 200 mg and C-peptide
Intervention: GABA 200 mgOutcome: C-peptide
1 results
All studies on GABA 200 mg and Counter-regulatory hormone response to hypoglycemia
Intervention: GABA 200 mgOutcome: Counter-regulatory hormone response to hypoglycemia
1 results
All studies on GABA 200 mg
Intervention: GABA 200 mg
1 results
All studies measuring C-peptide
Outcome: C-peptide
1 results
All studies measuring Counter-regulatory hormone response to hypoglycemia
Outcome: Counter-regulatory hormone response to hypoglycemia
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GABA 200 mg improve c-peptide?
Emerging Evidence
Current evidence does not show a clear benefit of GABA 200 mg for c-peptide.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
C-peptide
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does GABA 200 mg affect counter-regulatory hormone response to hypoglycemia?
Emerging Evidence
Current evidence does not show a clear effect of GABA 200 mg on counter-regulatory hormone response to hypoglycemia.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Counter-regulatory hormone response to hypoglycemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does GABA 200 mg improve elevated liver transaminase?
Emerging Evidence
Current evidence does not show a clear benefit of GABA 200 mg for elevated liver transaminase.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Elevated liver transaminase
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does GABA 200 mg improve fasting c-peptide levels?
Emerging Evidence
Current evidence does not show a clear benefit of GABA 200 mg for fasting c-peptide levels.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fasting C-peptide levels
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Adding diabetes medications to metformin improves glycemic control in adults with T2 diabetes.HRS-7535 improves glycemic control in adults with type 2 diabetesHigh-protein diet shows little effect on glycemic control in diabetesHybrid Closed-Loop Insulin Improves Glycemic Control in YouthLiraglutide and Empagliflozin Improve Heart Function in Diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.